JPS6360756B2 - - Google Patents
Info
- Publication number
- JPS6360756B2 JPS6360756B2 JP12171380A JP12171380A JPS6360756B2 JP S6360756 B2 JPS6360756 B2 JP S6360756B2 JP 12171380 A JP12171380 A JP 12171380A JP 12171380 A JP12171380 A JP 12171380A JP S6360756 B2 JPS6360756 B2 JP S6360756B2
- Authority
- JP
- Japan
- Prior art keywords
- theobromine
- formula
- piperazinyl
- group
- para
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- -1 p-toluenesulfonyloxy group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004559 theobromine Drugs 0.000 description 83
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- ANLAJHPNLDWXHU-UHFFFAOYSA-N 1-(4-bromobutyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCBr)C(=O)C2=C1N=CN2C ANLAJHPNLDWXHU-UHFFFAOYSA-N 0.000 description 1
- WTSBEXZNHFHRFY-UHFFFAOYSA-N 1-(7-bromoheptyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCCCBr)C(=O)C2=C1N=CN2C WTSBEXZNHFHRFY-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Description
本発明は、医薬品として優れた作用を有する新
規なテオブロミン誘導体およびその製造方法に関
する。
更に詳しくは一般式
〔式中Rは水素原子または低級アルキル基を示
し、Zは式
The present invention relates to a novel theobromine derivative having excellent effects as a pharmaceutical and a method for producing the same. For more details, see the general formula [In the formula, R represents a hydrogen atom or a lower alkyl group, and Z represents the formula
【式】(式中X1およびX2は
同一または異なつてそれぞれ水素原子、低級アル
キル基、低級アルコキシ基、トリフルオロメチル
基またはハロゲン原子を意味する)で示される
基、または式
(式中Y1およびY2は同一または異なつてそれぞ
れ水素原子、低級アルキル基、低級アルコキシ
基、トリフルオロメチル基またはハロゲン原子を
意味する)で示される基を意味する。nは2〜10
の整数を意味する〕で表わされるテオブロミン誘
導体およびその酸付加塩;ならびにその製造方法
に関するものである。
上記一般式〔〕において、R,X1,X2,Y1
およびY2の定義中にみられる低級アルキル基ま
たは低級アルコキシ基とは、炭素数1〜6の直鎖
若しくは分枝状のアルキル基、例えば、メチル、
エチル、n−プロピル、イソプロピル、イソブチ
ル、1−メチルプロピル、tert−ブチル、n−ペ
ンチル、1−エチルプロピル、イソアミル、n−
ヘキシル基などのアルキル基若しくは、これに基
づくアルコキシ基を意味する。またハロゲン原子
とは具体的には塩素、臭素、ヨウ素、フツ素を意
味する。
また本発明の化合物〔〕は、薬理的に許容さ
れる無機酸または有機酸と反応させて容易に酸付
加塩とすることができる。かかる無機酸としては
塩酸、臭化水素酸、ヨウ化水素酸、硫酸などを、
また有機酸としてはマレイン酸、フマール酸、コ
ハク酸、酢酸、マロン酸、クエン酸、安息香酸な
どを例示することができる。
次に本発明の代表的化合物の一例を列記する
が、本発明がこれらの化合物に限定されることが
ないことはいうまでもない。
Γ 1−{7−〔4−オルト−メトキシフエニルピ
ペラジニル−(1)〕−n−ヘプチル}−テオブロミ
ン
Γ 1−{6−〔4−オルト−メトキシフエニルピ
ペラジニル−(1)〕−n−ヘキシル}−テオブロミ
ン
Γ 1−{5−〔4−メタ−メトキシフエニルピペ
ラジニル−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{6−〔4−メタ−メトキシフエニルピペ
ラジニル−(1)〕−n−ヘキシル}−テオブロミン
Γ 1−{8−〔4−オルト−メトキシフエニルピ
ペラジニル−(1)〕−n−オクチル}−テオブロミ
ン
Γ 1−{10−〔4−メタ−メトキシフエニルピペ
ラジニル−(1)〕−n−デシル}−テオブロミン
Γ 1−{2−〔4−パラ−メトキシフエニルピペ
ラジニル−(1)〕−エチル}−テオブロミン
Γ 1−{4−〔4−オルト−エトキシフエニルピ
ペラジニル−(1)〕−n−ブチル}−テオブロミン
Γ 1−{4−〔4−オルト、メタ−ジメチルフエ
ニルピペラジニル−(1)〕−n−ブチル}−テオブ
ロミン
Γ 1−{2−〔4−(2,6−ジメチルフエニル)
ピペラジニル−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔4−(2,6−ジメチルフエニル)
−ピペラジニル(1)〕−n−プロピル}−テオブロ
ミン
Γ 1−{4−〔4−(2,6−ジメチルフエニル)
−ピペラジニル−(1)〕−n−ブチル}テオブロ
ミン
Γ 1−{5−〔4−(2,6−ジメチルフエニル)
ピペラジニル−(1)〕−n−ペンチル}−テオブロ
ミン
Γ 1−{2−〔4−(2,3−ジメチルフエニル)
ピペラジニル−(1)〕エチル}−テオブロミン
Γ 1−{3−〔4−(2,3−ジメチルフエニル)
ピペラジニル−(1)〕−n−プロピル}−テオブロ
ミン
Γ 1−{4−〔4−(2,3−ジメチルフエニル)
ピペラジニル−(1)〕−n−ブチル}−テオブロミ
ン
Γ 1−{5−〔4−(2,3,ジメチルフエニル)
ピペラジニル−(1)〕−n−ペンチル}−テオブロ
ミン
Γ 1−{6−〔4−(2,3−ジメチルフエニル)
ピペラジニル−(1)〕−n−ヘキシル}−テオブロ
ミン
Γ 1−{2−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−プロピル}−テオブロ
ミン
Γ 1−{4−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−ブチル}−テオブロミ
ン
Γ 1−{5−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−ペンチル}−テオブロ
ミン
Γ 1−{6−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−ヘキシル}−テオブロ
ミン
Γ 1−{7−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−ヘプチル}−テオブロ
ミン
Γ 1−{8−〔4−(2,3−ジメチルフエニル)
ピペラジニル−(1)〕−n−オクチル}−テオブロ
ミン
Γ 1−{9−〔4−(2,6−ジメチルフエニル)
ピペラジニル−(1)〕−n−ノニル}−テオブロミ
ン
Γ 1−{10−〔4−(2,5−ジメチルフエニル)
ピペラジニル−(1)〕−n−デシル}−テオブロミ
ン
Γ 1−{5−〔4−ベンツヒドリルピペラジニル
−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{2−〔4−ベンツヒドリルピペラジニル
−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔4−ベンツヒドリルピペラジニル
−(1)〕−n−プロピル}−テオブロミン
Γ 1−{4−〔4−ベンツヒドリルピペラジニル
−(1)〕−n−ブチル}−テオブロミン
Γ 1−{5−〔4−ベンツヒドリルピペラジニル
−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{6−〔4−ベンツヒドリルピペラジニル
−(1)〕−n−ヘキシル}−テオブロミン
Γ 1−{2−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−n−プロピル}−テオブロ
ミン
Γ 1−{4−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−2−ブチル}−テオブロミ
ン
Γ 1−{5−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−n−ペンチル}−テオブロ
ミン
Γ 1−{6−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−n−ヘキシル}−テオブロ
ミン
Γ 1−{10−〔4−パラ−メトキシベンツヒドリ
ルピペラジニル−(1)〕−n−デシル}−テオブロ
ミン
Γ 1−{4−〔4−(4′,4″−ジクロロフエニル
メチル)ピペラジニル−(1)〕−n−ブチル}−テ
オブロミン
Γ 1−{9−〔4−パラ−クロロベンツヒドリル
ピペラジニル−(1)〕−n−ノニル}−テオブロミ
ン
Γ 1−{8−〔4−パラ−メチルベンツヒドリル
ピペラジニル−(1)〕−n−オクチル}−テオブロ
ミン
Γ 1−{7−〔4−パラ−トリフルオロメチルベ
ンツヒドリルピペラジニル−(1)〕−n−ヘプチ
ル}−テオブロミン
Γ 1−{6−〔4−オルトメチルフエニルピペラ
ジニル−(1)〕−n−ヘキシル}−テオブロミン
Γ 1−{2−〔4−メタ−メチルフエニルピペラ
ジニル−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔4−パラ−メチルフエニルピペラ
ジニル−(1)〕−n−プロピル}−テオブロミン
Γ 1−{4−〔4−メタ−メチルフエニルピペラ
ジニル−(1)〕−n−ブチル}−テオブロミン
Γ 1−{5−〔4−パラ−メチルフエニルピペラ
ジニル−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{7−〔4−パラ−トリフルオロメチルピ
ペラジニル−(1)〕−n−ヘプチル}−テオブロミ
ン
Γ 1−{8−〔4−パラ−エトキシフエニルピペ
ラジニル−(1)〕−n−オクチル}−テオブロミン
Γ 1−{2−〔4−オルト−クロロフエニルピペ
ラジニル−(1)〕−n−エチル}−テオブロミン
Γ 1−{3−〔4−パラ−クロロフエニルピペラ
ジニル−(1)〕−n−プロピル}−テオブロミン
Γ 1−{4−〔4−オルト−クロロフエニルピペ
ラジニル−(1)〕−n−ブチル}−テオブロミン
Γ 1−{5−〔4−パラ−クロロフエニルピペラ
ジニル−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{6−〔4−メタ−クロロフエニルピペラ
ジニル−(1)〕−n−ヘキシル}−テオブロミン
Γ 1−{7−〔4−パラ−メトキシフエニルピペ
ラジニル−(1)〕−n−ヘプチル}−テオブロミン
Γ 1−{3−〔4−(3,4−ジクロロフエニル)
ピペラジニル−(1)〕−n−プロピル}−テオブロ
ミン
Γ 1−{4−〔4−(3,4−ジクロロフエニル)
ピペラジニル−(1)〕−n−ブチル}−テオブロミ
ン
Γ 1−{5−〔4−(3,4−ジクロロフエニル)
ピペラジニル−(1)〕−n−ペンチル}−テオブロ
ミン
Γ 1−{6−〔4−(2,3−ジクロロフエニル)
ピペラジニル−(1)〕−n−ヘキシル}−テオブロ
ミン
Γ 1−{7−〔4−(2,5−ジクロロフエニル)
ピペラジニル−(1)〕−n−ヘプチル}−テオブロ
ミン
Γ 1−{8−〔4−(2,6−ジクロロフエニル)
ピペラジニル−(1)〕−n−オクチル}−テオブロ
ミン
Γ 1−{9−〔4−(3,4−ジクロロフエニル)
ピペラジニル−(1)〕−n−ノニル}−テオブロミ
ン
Γ 1−{10−〔4−(3,4−ジクロロフエニル)
ピペラジニル−(1)〕−n−デシル}−テオブロミ
ン
Γ 1−{2−〔3−メチル−4−フエニルピペラ
ジニル−(1)〕−エチル}−テオブロミン
Γ 1−{3−〔3−メチル−4−フエニルピペラ
ジニル−(1)〕−n−プロピル}−テオブロミン
Γ 1−{4−〔3−メチル−4−フエニルピペラ
ジニル−(1)〕−n−ブチル}−テオブロミン
Γ 1−{5−〔3−メチル−4−フエニルピペラ
ジニル−(1)〕−n−ペンチル}−テオブロミン
Γ 1−{6−〔3−(メチル−4−フエニルピペ
ラジニル−(1)〕−n−ヘキシル}−テオブロミン
Γ 1−{2−〔3−メチル−4−パラ−メトキシ
フエニルピペラジニル−(1)〕−エチル}−テオブ
ロミン
Γ 1−{3−〔3−メチル−4−パラ−メトキシ
フエニルピペラジニル−(1)〕−n−プロピル}−
テオブロミン
Γ 1−{4−〔3−メチル−4−オルト−メトキ
シフエニルピペラジニル−(1)〕−n−ブチル}−
テオブロミン
Γ 1−{5−〔3−メチル−4−メタ−メトキシ
フエニルピペラジニル−(1)〕−n−ペンチル}−
テオブロミン
Γ 1−{7−〔4−パラ−フルオロフエニルピペ
ラジニル−(1)〕−n−ヘプチル}−テオブロミン
Γ 1−{10−〔3−(メチル−4−メタ−メトキ
シフエニルピペラジニル−(1)〕−n−デシル}−
テオブロミン
Γ 1−{10−〔4−(2,4−ジメチルフエニル
ピペラジニル−(1)〕−n−デシル}−テオブロミ
ン
本発明によつて提供されるテオブロミン誘導体
は、いずれも文献未収載の新規化合物であり、極
めめて著しい血管拡張作用、血流増加作用を有す
る化合物である。すなわち、本発明化合物は、脳
および冠状動脈の血流の改善、および末梢血流の
改善が顕著である。更に本発明化合物は血小板凝
集抑制作用をも有するので、末梢血流潅流の障害
に基づく種々の疾患の治療剤;脳血管障害および
その後遺症の改善;狭心症、心筋硬塞などの治療
剤として最適である。また本発明によつて提供さ
れるテオブロミン誘導体は、その他の有用な優れ
た薬理作用として、中枢神経系に対する作用、抗
ヒスタミン作用、鎮痛作用、抗喘息作用、降圧作
用をも有するので、向精神薬、抗ヒスタミン剤、
鎮痛剤、抗喘息薬、抗アレルギー剤、降圧剤とし
ても有用である。
本発明化合物〔〕は、種々の方法によつて製
造することができるが、その中で通常用いられる
方法の一例を示せば次の如くである。
(式中Xは、ハロゲン原子若しくはパラートル
エンスルホニルオキシ基を意味し、R,Zおよび
nは前記の意味を有する)
すなわち、一般式〔〕で表わされる化合物
と、一般式〔〕で表わされる化合物とを反応さ
せて本発明化合物〔〕を得る。
本反応は、無溶媒または例えばメタノール、エ
タノール、プロパノール、イソプロパノール等の
低級アルコール系、ベンゼン、トルエン、キシレ
ン等のベンゼン系、エチルエーーテル、テトラハ
イドフラン等のエーテル系溶媒から反応に関与し
ない溶媒を適宜選択して使用することができる。
反応は室温でも進行するが、好ましくは溶媒の沸
点まで加熱することが望ましい。反応に際しては
例えばトリエチルアミン、重炭酸アルカリ、炭酸
アルカリ、ピリジン等の脱酸剤を反応系に添加す
ることにより、反応を一層円滑におこなうことが
できる。
次に本発明化合物の優れた薬理作用を本発明の
代表的化合物について以下に詳細に説明する。
血流増加作用
1 実験方法
体重8〜20Kgの雌雄雑犬を用いて、椎骨動脈お
よび股動脈における血流を測定した。すなわちジ
エチルバルビタール(240mg/μg皮下注)およ
びペントバルビタールナトリウム(10mg/Kg静脈
注)で麻酔した犬の一側股動脈と一側椎骨動脈に
電磁血流計(日本光電MF−27型)のプローブを
装着した後、両動脈の血流を同時に測定した。検
体の投与は動脈穿針により体重1Kgあたり0.1μ
g、1μgおよび10μgの用量でおこなつた。血流
量の他に、血圧と心拍数を連続的に記録した。
2 実験結果
結果を表2に示す。
表1における血流増加の強度は、対照薬として
パパベリンを選び、その作用の強さと比較したも
ので、最小作用用量が0.1μg/Kgの検体をA、
1.0μg/Kgの検体をB、10μg/Kgの検体のうち
パパベリンより強いものをC、弱いものをD、作
用のでなかつた検体をEとして分類した。パパベ
リンの10例における血流増加量と持続時間は次に
示す表1の如くであつた。[Formula] (wherein X 1 and X 2 are the same or different and each means a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group, or a halogen atom), or a group represented by the formula (In the formula, Y 1 and Y 2 are the same or different and each means a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group, or a halogen atom). n is 2 to 10
Theobromine derivatives and acid addition salts thereof; and methods for producing the same. In the above general formula [], R, X 1 , X 2 , Y 1
The lower alkyl group or lower alkoxy group found in the definitions of
Ethyl, n-propyl, isopropyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 1-ethylpropyl, isoamyl, n-
It means an alkyl group such as a hexyl group, or an alkoxy group based on this. Moreover, the halogen atom specifically means chlorine, bromine, iodine, and fluorine. Furthermore, the compound [ ] of the present invention can be easily converted into an acid addition salt by reacting with a pharmacologically acceptable inorganic or organic acid. Such inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, etc.
Examples of organic acids include maleic acid, fumaric acid, succinic acid, acetic acid, malonic acid, citric acid, and benzoic acid. Examples of typical compounds of the present invention are listed below, but it goes without saying that the present invention is not limited to these compounds. Γ 1-{7-[4-ortho-methoxyphenylpiperazinyl-(1)]-n-heptyl}-theobromine Γ 1-{6-[4-ortho-methoxyphenylpiperazinyl-(1) ]-n-hexyl}-theobromine Γ 1-{5-[4-methoxyphenylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4-meta-methoxyphenylpiperazinyl-(1)]-n-pentyl}-theobromine Γ enylpiperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{8-[4-ortho-methoxyphenylpiperazinyl-(1)]-n-octyl}-theobromine Γ 1-{10 -[4-Meta-methoxyphenylpiperazinyl-(1)]-n-decyl}-theobromine Γ 1-{2-[4-para-methoxyphenylpiperazinyl-(1)]-ethyl}- Theobromine Γ 1-{4-[4-ortho-ethoxyphenylpiperazinyl-(1)]-n-butyl}-Theobromine Γ 1-{4-[4-ortho, meta-dimethylphenylpiperazinyl- (1)]-n-butyl}-theobromine Γ 1-{2-[4-(2,6-dimethylphenyl)
Piperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[4-(2,6-dimethylphenyl)
-piperazinyl(1)]-n-propyl}-theobromine Γ 1-{4-[4-(2,6-dimethylphenyl)
-piperazinyl-(1)]-n-butyl}theobromine Γ 1-{5-[4-(2,6-dimethylphenyl)
Piperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{2-[4-(2,3-dimethylphenyl)
Piperazinyl-(1)]ethyl}-theobromine Γ 1-{3-[4-(2,3-dimethylphenyl)
Piperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[4-(2,3-dimethylphenyl)
Piperazinyl-(1)]-n-butyl}-theobromine Γ 1-{5-[4-(2,3, dimethylphenyl)
Piperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4-(2,3-dimethylphenyl)
Piperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{2-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-butyl}-theobromine Γ 1-{5-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{7-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-heptyl}-theobromine Γ 1-{8-[4-(2,3-dimethylphenyl)
Piperazinyl-(1)]-n-octyl}-theobromine Γ 1-{9-[4-(2,6-dimethylphenyl)
Piperazinyl-(1)]-n-nonyl}-theobromine Γ 1-{10-[4-(2,5-dimethylphenyl)
Piperazinyl-(1)]-n-decyl}-theobromine Γ 1-{5-[4-benzhydrylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{2-[4-benz hydrylpiperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[4-benzhydrylpiperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[4 -benzhydrylpiperazinyl-(1)]-n-butyl}-theobromine Γ 1-{5-[4-benzhydrylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{ 6-[4-benzhydrylpiperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{2-[4-para-chlorobenzhydrylpiperazinyl-(1)]-ethyl}- Theobromine Γ 1-{3-[4-para-chlorobenzhydrylpiperazinyl-(1)]-n-propyl}-Theobromine Γ 1-{4-[4-para-chlorobenzhydrylpiperazinyl- (1)]-2-butyl}-theobromine Γ 1-{5-[4-para-chlorobenzhydrylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4- Para-chlorobenzhydrylpiperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{10-[4-para-methoxybenzhydrylpiperazinyl-(1)]-n-decyl}- Theobromine Γ 1-{4-[4-(4′,4″-dichlorophenylmethyl)piperazinyl-(1)]-n-butyl}-theobromine Γ 1-{9-[4-para-chlorobenzhydryl Piperazinyl-(1)]-n-nonyl}-theobromine Γ 1-{8-[4-para-methylbenzhydrylpiperazinyl-(1)]-n-octyl}-theobromine Γ 1-{7 -[4-para-trifluoromethylbenzhydrylpiperazinyl-(1)]-n-heptyl}-theobromine Γ 1-{6-[4-orthomethylphenylpiperazinyl-(1)]-n -hexyl}-theobromine Γ 1-{2-[4-meta-methylphenylpiperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[4-para-methylphenylpiperazinyl- (1)]-n-propyl}-theobromine Γ 1-{4-[4-meta-methylphenylpiperazinyl-(1)]-n-butyl}-theobromine Γ 1-{5-[4-para -methylphenylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{7-[4-para-trifluoromethylpiperazinyl-(1)]-n-heptyl}-theobromine Γ 1 -{8-[4-para-ethoxyphenylpiperazinyl-(1)]-n-octyl}-theobromine Γ 1-{2-[4-ortho-chlorophenylpiperazinyl-(1)]-n -ethyl}-theobromine Γ 1-{3-[4-para-chlorophenylpiperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[4-ortho-chlorophenylpiperazinyl- (1)]-n-butyl}-theobromine Γ 1-{5-[4-para-chlorophenylpiperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4-meth- Chlorophenylpiperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{7-[4-para-methoxyphenylpiperazinyl-(1)]-n-heptyl}-theobromine Γ 1-{ 3-[4-(3,4-dichlorophenyl)
Piperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[4-(3,4-dichlorophenyl)
Piperazinyl-(1)]-n-butyl}-theobromine Γ 1-{5-[4-(3,4-dichlorophenyl)
Piperazinyl-(1)]-n-pentyl}-theobromine Γ 1-{6-[4-(2,3-dichlorophenyl)
Piperazinyl-(1)]-n-hexyl}-theobromine Γ 1-{7-[4-(2,5-dichlorophenyl)
Piperazinyl-(1)]-n-heptyl}-theobromine Γ 1-{8-[4-(2,6-dichlorophenyl)
Piperazinyl-(1)]-n-octyl}-theobromine Γ 1-{9-[4-(3,4-dichlorophenyl)
Piperazinyl-(1)]-n-nonyl}-theobromine Γ 1-{10-[4-(3,4-dichlorophenyl)
Piperazinyl-(1)]-n-decyl}-theobromine Γ 1-{2-[3-methyl-4-phenylpiperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[3- Methyl-4-phenylpiperazinyl-(1)]-n-propyl}-theobromine Γ 1-{4-[3-methyl-4-phenylpiperazinyl-(1)]-n-butyl}- Theobromine Γ 1-{5-[3-methyl-4-phenylpiperazinyl-(1)]-n-pentyl}-Theobromine Γ 1-{6-[3-(methyl-4-phenylpiperazinyl) -(1)]-n-hexyl}-theobromine Γ 1-{2-[3-methyl-4-para-methoxyphenylpiperazinyl-(1)]-ethyl}-theobromine Γ 1-{3-[ 3-Methyl-4-para-methoxyphenylpiperazinyl-(1)]-n-propyl}-
Theobromine Γ 1-{4-[3-methyl-4-ortho-methoxyphenylpiperazinyl-(1)]-n-butyl}-
Theobromine Γ 1-{5-[3-methyl-4-meta-methoxyphenylpiperazinyl-(1)]-n-pentyl}-
Theobromine Γ 1-{7-[4-para-fluorophenylpiperazinyl-(1)]-n-heptyl}-Theobromine Γ 1-{10-[3-(methyl-4-methoxyphenylpipe Radinyl-(1)]-n-decyl}-
Theobromine Γ 1-{10-[4-(2,4-dimethylphenylpiperazinyl-(1)]-n-decyl}-theobromine None of the theobromine derivatives provided by the present invention are listed in literature. It is a novel compound with extremely significant vasodilatory and blood flow increasing effects.In other words, the compound of the present invention significantly improves blood flow in the brain and coronary arteries, as well as peripheral blood flow. Furthermore, since the compound of the present invention also has a platelet aggregation inhibitory effect, it can be used as a therapeutic agent for various diseases caused by disorders of peripheral blood perfusion; for improving cerebrovascular disorders and their sequelae; for treating angina pectoris, myocardial infarction, etc. In addition, the theobromine derivatives provided by the present invention also have other useful and excellent pharmacological effects such as action on the central nervous system, antihistamine action, analgesic action, anti-asthma action, and antihypertensive action. psychotropic drugs, antihistamines,
It is also useful as an analgesic, anti-asthmatic agent, anti-allergy agent, and antihypertensive agent. The compound of the present invention [] can be produced by various methods, and an example of a commonly used method is as follows. (In the formula, X means a halogen atom or a p-toluenesulfonyloxy group, and R, Z and n have the above-mentioned meanings.) That is, a compound represented by the general formula [] and a compound represented by the general formula [] The compound of the present invention [] is obtained by reacting with This reaction can be carried out without a solvent or with a solvent that does not participate in the reaction, such as lower alcohols such as methanol, ethanol, propanol, and isopropanol, benzenes such as benzene, toluene, and xylene, and ethers such as ethyl ether and tetrahydrofuran. It can be selected and used as appropriate.
Although the reaction proceeds at room temperature, it is preferable to heat the reaction to the boiling point of the solvent. The reaction can be carried out more smoothly by adding a deoxidizing agent such as triethylamine, alkali bicarbonate, alkali carbonate, or pyridine to the reaction system. Next, the excellent pharmacological effects of the compounds of the present invention will be explained in detail with respect to representative compounds of the present invention. Blood flow increasing effect 1 Experimental method Blood flow in the vertebral artery and femoral artery was measured using mongrel dogs of both sexes weighing 8 to 20 kg. That is, the probe of an electromagnetic blood flow meter (Nihon Kohden MF-27 model) was inserted into the unilateral femoral artery and unilateral vertebral artery of a dog anesthetized with diethylbarbital (240 mg/μg subcutaneous injection) and pentobarbital sodium (10 mg/Kg intravenous injection). After attaching the device, blood flow in both arteries was measured simultaneously. The sample was administered at a dose of 0.1μ per kg of body weight by arterial puncture.
doses of 1 μg, 1 μg and 10 μg. In addition to blood flow, blood pressure and heart rate were continuously recorded. 2 Experimental Results The results are shown in Table 2. The strength of blood flow increase in Table 1 is compared with the strength of the effect of papaverine selected as a control drug.
The 1.0 μg/Kg sample was classified as B, the 10 μg/Kg sample was classified as C, the one stronger than papaverine was classified as D, the weaker one was classified as D, and the sample with no effect was classified as E. The amount and duration of increase in blood flow in the 10 patients treated with papaverine were as shown in Table 1 below.
【表】【table】
【表】
表2より、本発明化合物は、極めて優れた血流
増加作用を有することとが明らかである。
以下に、本発明を更に詳細に説明するため実施
例を示すが、本発明がそれのみに限定されること
がないことはいうまでもない。
実施例 1
1−{4−〔4−オルト、メタ−ジメチルフエニ
ルピペラジニル−(1)〕−n−ブチル}−テオブロ
ミン
1−(4−ブロモ−n−ブチル)テオブロミン
9.5g、オルト、メタ−ジメチルフエニルピペラ
ジン3.8g、およびトリエチルアミン4.0gをトル
エン中13時間還流下撹拌する。トリエチルアミン
の塩酸塩を去し、液を稀塩酸で抽出する。稀
水酸化ナトリウムでアルカリ性にした後クロロホ
ルムで抽出する。クロロホルム層を水洗後無水炭
酸カリウムで乾燥する。溶媒を留去し得られた粗
結晶をメチルセロソルブで再結晶して標題の1−
{4−〔4−オルト、メタ−ジメチルフエニルピペ
ラジニル−(1)〕−n−ブチル}−テオブロミンを
3.7g(収率43.64%)を得る。
融点:134〜135℃
元素分析値:C23H32O2N6として
C H N
理論値(%) 65.05 7.61 19.80
実測値(%) 65.11 7.72 19.46
実施例 2
1−{5−〔4−ペンツヒドリルピペラジニル−
(1)〕−n−ペンチル}−テオブロミン・塩酸塩
1−(5−ブロモ−2−ペンチル)テオブロミ
ン7.9g,N−ペンツヒドリルピペラジン5.0g、
およびトリエチルアミン4gをトルエン中30時間
還流下撹拌する。以後の操作は実施例1と同様の
処理におこない、得られた粗結晶は常法により塩
酸塩とする。イソプロピルアルコールにより再結
晶して標題の1−{5−〔4−ベンツヒドリルピペ
ラジニル−(1)〕−n−ペンチル}−テオブロミン・
塩酸塩を4.7g(収率40.9%)を得る。
融点:262〜264℃(分解)
元素分析値:C29H36O2N6・2HClとして
C H N
理論値(%) 60.93 6.71 14.71
実測値(%) 60.57 7.15 14.65
実施例 3
1−{7−〔4−オルト−メトキシフエニルピペ
ラジニル−(1)〕−n−ヘプチル}−テオブロミン
1−(7ブロモ−n−ヘプチル)テオブロミン
7.5g、N−オルトメトキシフエニルピペラジン
3.8g、およびトリエチルアミン4.0gをトルエン
中11.5時間還流撹拌する。以後実施例1と同様に
処理し、粗結晶を得る。シリカゲルクロマトグラ
フイーにて精製し、標題の1−{7−〔4−オルト
−メトキシフエニルピペラジニル−(1)〕−n−ヘ
プペチル}−テオブロミン4.6g(収率49.1%)を
得る。
融点:97〜98℃
元素分析値:C25H36O3N6として
C H N
理論値(%) 64.08 7.74 17.94
実測値(%) 63.90 7.67 18.01
実施例 4〜53
実施例1の方法に準じた方法により表3に示す
化合物が得られた。[Table] From Table 2, it is clear that the compounds of the present invention have an extremely excellent effect of increasing blood flow. Examples are shown below to explain the present invention in more detail, but it goes without saying that the present invention is not limited thereto. Example 1 1-{4-[4-ortho, meta-dimethylphenylpiperazinyl-(1)]-n-butyl}-theobromine 1-(4-bromo-n-butyl)theobromine
9.5 g of ortho, meta-dimethylphenylpiperazine, and 4.0 g of triethylamine are stirred in toluene under reflux for 13 hours. The triethylamine hydrochloride was removed and the solution was extracted with dilute hydrochloric acid. After making alkaline with dilute sodium hydroxide, extract with chloroform. The chloroform layer is washed with water and then dried with anhydrous potassium carbonate. The crude crystals obtained by distilling off the solvent were recrystallized with methyl cellosolve to obtain the title 1-
{4-[4-ortho, meta-dimethylphenylpiperazinyl-(1)]-n-butyl}-theobromine
Obtain 3.7 g (yield 43.64%). Melting point: 134-135℃ Elemental analysis value: C 23 H 32 O 2 N 6 Theoretical value (%) 65.05 7.61 19.80 Actual value (%) 65.11 7.72 19.46 Example 2 1-{5-[4-pen Tuhydrylpiperazinyl
(1)]-n-pentyl}-theobromine hydrochloride 1-(5-bromo-2-pentyl)theobromine 7.9 g, N-penthydrylpiperazine 5.0 g,
and 4 g of triethylamine were stirred in toluene under reflux for 30 hours. The subsequent operations are carried out in the same manner as in Example 1, and the obtained crude crystals are converted into hydrochloride by a conventional method. Recrystallization from isopropyl alcohol yields the title 1-{5-[4-benzhydrylpiperazinyl-(1)]-n-pentyl}-theobromine.
4.7 g (yield 40.9%) of hydrochloride is obtained. Melting point: 262-264℃ (decomposition) Elemental analysis value: C 29 H 36 O 2 N 6・2HCl C H N Theoretical value (%) 60.93 6.71 14.71 Actual value (%) 60.57 7.15 14.65 Example 3 1-{7 -[4-ortho-methoxyphenylpiperazinyl-(1)]-n-heptyl}-theobromine 1-(7bromo-n-heptyl)theobromine
7.5g, N-orthomethoxyphenylpiperazine
3.8 g and 4.0 g of triethylamine are stirred at reflux in toluene for 11.5 hours. Thereafter, the same treatment as in Example 1 is carried out to obtain crude crystals. Purification by silica gel chromatography yields 4.6 g (yield: 49.1%) of the title 1-{7-[4-ortho-methoxyphenylpiperazinyl-(1)]-n-hepeptyl}-theobromine. Melting point: 97-98°C Elemental analysis value: C 25 H 36 O 3 N 6 Theoretical value (%) 64.08 7.74 17.94 Actual value (%) 63.90 7.67 18.01 Examples 4-53 According to the method of Example 1 The compounds shown in Table 3 were obtained by the method described above.
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
Claims (1)
し、Zは式【式】(式中X1およびX2は 同一または異なつてそれぞれ水素原子、低級アル
キル基、低級アルコキシ基、トリフルオロメチル
基またはハロゲン原子を意味する)で示される
基、または式【式】(式中Y1 およびY2は同一または異なつてそれぞれ水素原
子、低級アルキル基、低級アルコキシ基、トリフ
ルオロメチル基またはハロゲン原子を意味する)
で示される基を意味する。nは2〜10の整数を示
す。〕で表わされるテオブロミン誘導体およびそ
の酸付加塩。 2 一般式 (式中nは2〜10の整数を意味し、Xはハロゲ
ン原子若しくはパラートルエンスルホニルオキシ
基を意味する)で表わされる化合物に、一般式 〔式中Rは水素原子または低級アルキル基を示
し、Zは式【式】(式中X1およびX2は 同一または異なつてそれぞれ水素原子、低級アル
キル基、低級アルコキシ基、トリフルオロメチル
基またはハロゲン原子を意味する)で示される
基、または式【式】(式中Y1 およびY2は同一または異なつてそれぞれ水素原
子、低級アルキル基、低級アルコキシ基、トリフ
ルオロメチル基またはハロゲン原子を意味する)
で示される基を意味する〕で表わされる化合物を
反応させることを特徴とする一般式 (式中n,RおよびZは前記した意味を有す
る)で表わされるテオブロミン誘導体の製造方
法。[Claims] 1. General formula [In the formula, R represents a hydrogen atom or a lower alkyl group , and Z represents the formula halogen atom), or a group represented by the formula [Formula] (where Y 1 and Y 2 are the same or different and each represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group, or a halogen atom) do)
means a group represented by n represents an integer of 2 to 10. ] Theobromine derivatives and acid addition salts thereof. 2 General formula (In the formula, n means an integer of 2 to 10, and X means a halogen atom or p-toluenesulfonyloxy group.) [In the formula, R represents a hydrogen atom or a lower alkyl group , and Z represents the formula halogen atom), or a group represented by the formula [Formula] (where Y 1 and Y 2 are the same or different and each represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a trifluoromethyl group, or a halogen atom) do)
A general formula characterized by reacting a compound represented by A method for producing a theobromine derivative represented by the formula (in which n, R and Z have the above-mentioned meanings).
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12171380A JPS5746984A (en) | 1980-09-04 | 1980-09-04 | Theobromine derivative and its preparation |
US06/298,227 US4426383A (en) | 1980-09-04 | 1981-08-31 | Theophylline and theobromine derivatives |
NL8104073A NL8104073A (en) | 1980-09-04 | 1981-09-02 | "THEOPHYLLINE AND THEOBROMINE DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF. |
ES505184A ES505184A0 (en) | 1980-09-04 | 1981-09-03 | A PROCEDURE FOR THE PREPARATION OF THIOPHILINE OR THEOBROMINE DERIVATIVES. |
CA000385142A CA1172632A (en) | 1980-09-04 | 1981-09-03 | Theophylline and theobromine derivatives |
GB8126653A GB2083470B (en) | 1980-09-04 | 1981-09-03 | Theophylline and theobromine derivatives |
SE8105240A SE456910B (en) | 1980-09-04 | 1981-09-03 | 7-SUBSTITUTED THEOPHYLLINE, MADE TO PREPARE THIS AND A PHARMACEUTICAL COMPOSITION |
DE19813134929 DE3134929A1 (en) | 1980-09-04 | 1981-09-03 | DERIVATIVES OF THEOPHYLLIN AND THEOBROMIN |
CH5675/81A CH651042A5 (en) | 1980-09-04 | 1981-09-03 | THEOPHYLLIN AND THEOBROMIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
IT23790/81A IT1138196B (en) | 1980-09-04 | 1981-09-04 | COMPOUND DERIVED FROM THEOPHYLLINE OR THEOBROMINE |
FR8116855A FR2489331A1 (en) | 1980-09-04 | 1981-09-04 | THEOPHYLLINE AND THEOBROMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING SAME |
US06/484,044 US4564617A (en) | 1980-09-04 | 1983-04-11 | Theophylline and theobromine derivatives |
SE8704599A SE457083B (en) | 1980-09-04 | 1987-11-20 | 1-SUBSTITUTED THEOBROMINE, MADE TO MANUFACTURE THIS AND A PHARMACEUTICAL COMPOSITION |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12171380A JPS5746984A (en) | 1980-09-04 | 1980-09-04 | Theobromine derivative and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5746984A JPS5746984A (en) | 1982-03-17 |
JPS6360756B2 true JPS6360756B2 (en) | 1988-11-25 |
Family
ID=14818031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12171380A Granted JPS5746984A (en) | 1980-09-04 | 1980-09-04 | Theobromine derivative and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5746984A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6112605U (en) * | 1984-06-28 | 1986-01-24 | 富士通株式会社 | finger chuck joint |
JPS6274541A (en) * | 1985-09-30 | 1987-04-06 | Toshiba Corp | Complex lathe |
JPS62176717A (en) * | 1986-01-29 | 1987-08-03 | Mitsubishi Electric Corp | Electric discharge machine |
JP2551679Y2 (en) * | 1991-09-27 | 1997-10-27 | 豊田工機株式会社 | Attachment exchange device |
CA2302453A1 (en) * | 1997-09-16 | 1999-03-25 | Atsuhiro Inaba | Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs |
-
1980
- 1980-09-04 JP JP12171380A patent/JPS5746984A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5746984A (en) | 1982-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2852659B2 (en) | Piperazine derivatives and their salts | |
AU2014267974B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
JP2000072773A (en) | Purine derivative | |
LU84011A1 (en) | 2-PHENOXYALKYL-1,2,4-TRIAZOL-3-ONES ANTIDEPRESSIVE | |
JP2002507611A (en) | Imidazolone appetite suppressants: II. Phenyl derivative | |
JPH054391B2 (en) | ||
US5290776A (en) | Azole derivatives | |
RU2162848C2 (en) | Derivatives of oxa- or thiadizole, methods of their synthesis (variants), pharmaceutical composition | |
EP0266989B1 (en) | Dihydropyridine anti-allergic and anti-inflammatory agents | |
JP2000503667A (en) | Alkylaminobenzothiazole and -benzoxazole derivatives | |
JPH0641095A (en) | Antidepressant 3-halophenylpiperazinyl-propyl derivative of substituted triazolone and triazoledione | |
IE65125B1 (en) | Imidazopyridine PAF/H1 antagonists | |
AU5341394A (en) | Dopamine receptor subtype ligands | |
JP4833832B2 (en) | Pyrazole compounds | |
JP2860689B2 (en) | Pyrimidine derivatives | |
JPS6360756B2 (en) | ||
EP0329357B1 (en) | Dihydropyridine anti-allergic and anti-inflammatory agents | |
JP4018145B2 (en) | 4-[(thien-2-yl) methyl] imidazole derivatives having α2-adrenergic receptor agonist activity | |
CZ2004639A3 (en) | Deuterated pyrazolopyrimidinones and medicaments in which said compounds are comprised | |
JP2873417B2 (en) | Method for producing phenylalkanoate intermediate | |
CZ284350B6 (en) | DERIVATIVES OF 1,3-DIHYDRO-2H-PYRROLO[2,3-b]QUINOLIN-2-ONE, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | |
JP3302647B2 (en) | Phenyl alkanoate hydrochloride and method for producing the same | |
JPH07258217A (en) | New substituted sulfonamide, its production and medicinal composition containing same | |
CN114671878B (en) | Substituted nitrogen-containing bicyclic compounds and uses thereof | |
EP0254527A2 (en) | Tetracyclic indole derivatives |